EUVIMEDEUVIMED entdecken
Crossref

Real-world outcomes after anifrolumab initiation in systemic lupus erythematosus: a pragmatic treat-to-target analysis

Dalifer Freites Núñez, Paloma Camarero Diaz, Sara Rodríguez Montes, Cristina Martínez Prada, Cristina Lajas Petisco, Lydia Abasolo, Benjamin Fernández Gutierrez

Clinical Rheumatology · 2026-12 · 45 (12) · 7295-7303

DOI: 10.1007/s10067-026-08455-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Rheumatology, online erschienen am 05.10.2026. Verfasst von Dalifer Freites Núñez und 6 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Department, Hospital Universitario Clínico San Carlos, Prof. Martín Lagos s/n, 28040, Madrid, Spain. daliferdayanira.freites@salud.madri…. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Antibodies, Monoclonal, Humanized, Antirheumatic Agents. Die Arbeit nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION/OBJECTIVES: Treat-to-target (T2T) strategies in systemic lupus erythematosus (SLE) emphasise remission or low disease activity together with glucocorticoid minimisation. Real-world evidence evaluating anifrolumab using predefined target-oriented outcomes remains limited. We evaluated outcomes after anifrolumab initiation within a pragmatic T2T framework. METHODS: This retrospective single-centre cohort included adults with SLE receiving anifrolumab. The study-defined pragmatic low disease activity composite required SLEDAI-2K ≤ 4, Physician Global Assessment ≤ 1, prednisone ≤ 7.5 mg/day, and absence of clinically significant renal activity. Prednisone ≤ 5 mg/day was explored in sensitivity analyses. Outcomes were assessed at baseline and 1, 3, 6, and 12 months. Longitudinal changes in SLEDAI-2K, PGA, and prednisone dose were analysed using linear mixed-effects models. RESULTS: Nineteen patients were included (median baseline SLEDAI-2K 12.0 and median PGA 2.0). Composite attainment using prednisone ≤ 7.5 mg/day was 5.3% at 1 month, 47.4% at 3 months, 50.0% at 6 months, and 8/12 (66.7%) at 12 months. Using prednisone ≤ 5 mg/day, attainment was 36.8% at 3 months, 50.0% at 6 months, and 66.7% at 12 months. Disease activity components were met earlier than glucocorticoid thresholds. Mixed-effects models showed significant reductions in SLEDAI-2K, PGA, and prednisone dose during follow-up. One patient permanently discontinued anifrolumab due to influenza A, and one temporarily interrupted treatment because of pneumonia. CONCLUSIONS: After anifrolumab initiation, the proportion of evaluable patients meeting the pragmatic composite increased alongside reductions in disease activity and glucocorticoid dose. These exploratory findings suggest a potential role for anifrolumab within T2T strategies and warrant confirmation in larger controlled studies using validated treatment targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicAntibodies, Monoclonal, HumanizedAntirheumatic AgentsHumansFemaleAdultRetrospective StudiesPrednisoneMaleTreatment OutcomeMiddle AgedGlucocorticoidsSeverity of Illness Index

Stichwörter der Autor:innen

AnifrolumabGlucocorticoidsLow disease activityLupus erythematosus, systemicReal-world evidenceTreat-to-target

Substanzen

Antibodies, Monoclonal, HumanizedPrednisoneGlucocorticoidsanifrolumabAntirheumatic Agents

Autor:innen und Institutionen

  • Rheumatology Department, Hospital Universitario Clínico San Carlos, Prof. Martín Lagos s/n, 28040, Madrid, Spain. daliferdayanira.freites@salud.madrid.org.
  • Grupo de Patología Musculoesquelética, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain. daliferdayanira.freites@salud.madrid.org.
  • Rheumatology Department, Hospital Universitario Clínico San Carlos, Prof. Martín Lagos s/n, 28040, Madrid, Spain.
  • Grupo de Patología Musculoesquelética, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain.

Zitieren

APA

Núñez, D. F., Diaz, P. C., Montes, S. R., Prada, C. M., Petisco, C. L., Abasolo, L., & Gutierrez, B. F. (2026). Real-world outcomes after anifrolumab initiation in systemic lupus erythematosus: a pragmatic treat-to-target analysis. Clinical Rheumatology, 45(12), 7295-7303. https://doi.org/10.1007/s10067-026-08455-7

Vancouver

Núñez DF, Diaz PC, Montes SR, Prada CM, Petisco CL, Abasolo L, et al. Real-world outcomes after anifrolumab initiation in systemic lupus erythematosus: a pragmatic treat-to-target analysis. Clinical Rheumatology. 2026;45(12):7295-7303. doi:10.1007/s10067-026-08455-7

BibTeX
@article{Nez2026,
  author = {Núñez, Dalifer Freites and Diaz, Paloma Camarero and Montes, Sara Rodríguez and Prada, Cristina Martínez and Petisco, Cristina Lajas and Abasolo, Lydia and Gutierrez, Benjamin Fernández},
  title = {Real-world outcomes after anifrolumab initiation in systemic lupus erythematosus: a pragmatic treat-to-target analysis},
  journal = {Clinical Rheumatology},
  year = {2026},
  volume = {45},
  number = {12},
  pages = {7295--7303},
  doi = {10.1007/s10067-026-08455-7}
}
Kostenlos starten →